Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

Novo Nordisk received approval from the Food and Drug Administration for three new indications of Sogroya, a growth hormone.

Novo Nordisk’s post-trial sell-off may be overdone. Click here for this comparative analysis of NVO and LLY stocks and see their valuation vs. realistic growth.

Novo Nordisk will slash U.S. list prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 50% starting next year to $675 a month, the Danish ...

Shares of Novo Nordisk (NVO 0.29%) sank 20% this week, according to data from S&P Global Market Intelligence. The drugmaker ...

Novo Nordisk and Vivtex Corporation have entered into a partnership to develop next-generation oral biologic medicines for ...

Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be available this spring.

Novo Nordisk is deeply undervalued, trading at distressed multiples despite a robust pipeline and strong financials. Learn ...

For some reason, YouTube is convinced that my husband is a fat Latino. Apparently, watching hours-long videos of classical music, the occasional pickleball championship, and indulging in a daily dose ...

Vet visits typically cost between $50 to $250. Learn what factors affect vet visit pricing, how much pet insurance may cover, ...

Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026.

Novo Nordisk is suing a Shrewsbury doctor who sells a cheaper compounded medicine version of its popular Ozempic and Wegovy ...